Chris Shibutani

On Wednesday, Johnson & Johnson (NYSE:JNJ) reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the consensus of $2.01. The pharmaceutical giant reported sales of $22.52 billion, up 5.3% year over year and beating the consensus of $22.44 billion. Operational...

Eli Lilly & Co. (NYSE:LLY) shares have nosedived 12.5% month-to-date through Nov. 19, putting the stock on track for its worst monthly performance since February 2009, when it tumbled 20.2%. The pharmaceutical giant, which ranks 11th by market capitalization in the S&P 500 and holds the...

Eli Lilly And Co (NYSE:LLY) reported on Thursday second-quarter revenue of $11.3 billion, up 36% year-over-year, easily surpassing the consensus of $9.95 billion. Mounjaro sales tripled to $3.09 billion from $979.7 million a year ago. Zepbound sales reached $1.24 billion, up from $...

Bristol-Myers Squibb Co (NYSE:BMY) on Friday reported upbeat second-quarter results. The report came amid an exciting earnings season. Here are some key analyst takeaways. Barclays On Bristol-Myers Squibb Analyst Carter Gould downgraded the rating to Underweight, while maintaining the price target...

United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ: LQDA). While the company’s franchise position within the “highly attractive” pulmonary arterial hypertension (PAH) market is unique, its key growth asset faces significant competition...

Shares of Pfizer Inc. (NYSE: PFE) have been rallying in Tuesday’s trading. The company’s product pipeline and new launches offset the COVID-19 uncertainty in 2023, according to Goldman Sachs. The Analyst: Chris Shibutani upgraded the rating for Pfizer from Neutral to Buy, while raising...

Esperion Therapeutics Inc (NASDAQ: ESPR) stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. While the company hit its primary endpoints with the trial, patients in the test group experienced a higher...

Puma Biotechnology Inc (NASDAQ: PBYI) could face a setback in the launch of its breast cancer drug neratinib, as the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, relayed a "negative trend vote" after a meeting with the biotech company. ...